Published in Vaccine Weekly, April 19th, 1999
The trial is in addition to a multicenter, Phase I/II trial which began in December 1998 and enrolls approximately 40 earlier stage patients who have not yet received hormone therapy. Both of these expanded trials were prompted by encouraging results in the initial study of GVAX prostate cancer vaccine conducted in 1998 which demonstrated that the treatment was safe and well-tolerated and resulted in antitumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly